{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007861","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.987148+00:00","generated_at":"2026-06-18T03:22:33.857353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023","bullets":["Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.","Net loss for FY2022 was $68.2M ($1.01 per share) vs $54.6M ($1.04 per share) in 2021.","R&D expenses for FY2022 increased to $51.0M from $38.9M, driven by advancing zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis to initiate in H1 2023; PORTOLA Phase 2a in autoimmune hepatitis ongoing.","KZR-261 dose escalation currently enrolling Cohort 6; dose expansion study planned for H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007861","json":"https://secwatch.observer/filing/0000950170-23-007861.json","markdown":"https://secwatch.observer/filing/0000950170-23-007861.md","text":"https://secwatch.observer/filing/0000950170-23-007861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/0000950170-23-007861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/kzr-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:22:33.857353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}